Current status of cell-based therapies for respiratory virus infections: applicability to COVID-19

Simple item page
dc.coverageDOI: 10.1183/13993003.00858-2020
dc.creatorKhoury, Maroun
dc.creatorCuenca, Jimena
dc.creatorCruz, Fernanda F.
dc.creatorFigueroa, Fernando E.
dc.creatorRocco, Patricia R.M.
dc.creatorWeiss, Daniel J.
dc.date2020
dc.date.accessioned2025-11-18T19:53:46Z
dc.date.available2025-11-18T19:53:46Z
dc.description<p>The severe respiratory consequences of the coronavirus disease 2019 (COVID-19) pandemic have prompted urgent need for novel therapies. Cell-based approaches, primarily using mesenchymal stem (stromal) cells (MSCs), have demonstrated safety and possible efficacy in patients with acute respiratory distress syndrome (ARDS), although they are not yet well studied in respiratory virus-induced ARDS. Limited pre-clinical data suggest that systemic MSC administration can significantly reduce respiratory virus (influenza strains H5N1 and H9N2)-induced lung injury; however, there are no available data in models of coronavirus respiratory infection. There is a rapidly increasing number of clinical investigations of cell-based therapy approaches for COVID-19. These utilise a range of different cell sources, doses, dosing strategies and targeted patient populations. To provide a rational strategy to maximise potential therapeutic use, it is critically important to understand the relevant pre-clinical studies and postulated mechanisms of MSC actions in respiratory virus-induced lung injuries. This review presents these, along with consideration of current clinical investigations. </p>eng
dc.descriptionThe severe respiratory consequences of the coronavirus disease 2019 (COVID-19) pandemic have prompted urgent need for novel therapies. Cell-based approaches, primarily using mesenchymal stem (stromal) cells (MSCs), have demonstrated safety and possible efficacy in patients with acute respiratory distress syndrome (ARDS), although they are not yet well studied in respiratory virus-induced ARDS. Limited pre-clinical data suggest that systemic MSC administration can significantly reduce respiratory virus (influenza strains H5N1 and H9N2)-induced lung injury; however, there are no available data in models of coronavirus respiratory infection.<br/><br/>There is a rapidly increasing number of clinical investigations of cell-based therapy approaches for COVID-19. These utilise a range of different cell sources, doses, dosing strategies and targeted patient populations. To provide a rational strategy to maximise potential therapeutic use, it is critically important to understand the relevant pre-clinical studies and postulated mechanisms of MSC actions in respiratory virus-induced lung injuries. This review presents these, along with consideration of current clinical investigations.spa
dc.identifierhttps://investigadores.uandes.cl/en/publications/3a20d8dc-4397-4e93-8bcb-10f4c63ce719
dc.identifier.urihttps://repositorio.uandes.cl/handle/uandes/58415
dc.languageeng
dc.rightsinfo:eu-repo/semantics/openAccess
dc.sourcevol.55 (2020) date: 2020-06-01 nr.6
dc.subjectAnimals
dc.subjectBetacoronavirus
dc.subjectCell- and Tissue-Based Therapy
dc.subjectCoronavirus Infections
dc.subjectCulture Media, Conditioned
dc.subjectExtracellular Vesicles
dc.subjectHumans
dc.subjectInfluenza A Virus, H5N1 Subtype
dc.subjectInfluenza A Virus, H9N2 Subtype
dc.subjectInfluenza, Human
dc.subjectLung Injury
dc.subjectMesenchymal Stem Cell Transplantation
dc.subjectMesenchymal Stem Cells
dc.subjectOrthomyxoviridae Infections
dc.subjectPandemics
dc.subjectPeptidyl-Dipeptidase A
dc.subjectPneumonia, Viral
dc.subjectRespiratory Distress Syndrome, Adult
dc.subjectSerine Endopeptidases
dc.titleCurrent status of cell-based therapies for respiratory virus infections: applicability to COVID-19eng
dc.typeReview articleeng
dc.typeArtículo de revisiónspa
Files
Collections
PURE